Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Dow Jones12-12

By Josh Beckerman

Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its workforce.

The stock was recently down 76% to 30 cents. The stock closed at $1.28 on Tuesday, and is now down 90% year to date.

Due to recent communications with the Food and Drug Administration regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company said Tuesday that will pursue strategic options for the further development and commercialization of this drug candidate.

"While iopofosine I 131's positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources," the company said.

Cellectar said it will focus resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. It expects to file investigational new drug applications for both drug candidates in the first half of 2025.

The strategic reprioritization will impact all departments and result in an immediate reduction in headcount of about 60%, the company said. It expects the headcount reduction to be complete by the end of the fourth quarter.

Cellectar expects the restructuring will extend its cash runway into the third quarter of 2025.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

December 11, 2024 13:29 ET (18:29 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490962688?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490962688","market":"us","top_or_hot":-1,"title":"Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its workforce. \n</p>\n<p>\n  The stock was recently down 76% to 30 cents. The stock closed at $1.28 on Tuesday, and is now down 90% year to date. \n</p>\n<p>\n  Due to recent communications with the Food and Drug Administration regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company said Tuesday that will pursue strategic options for the further development and commercialization of this drug candidate. \n</p>\n<p>\n  \"While iopofosine I 131's positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources,\" the company said. \n</p>\n<p>\n  Cellectar said it will focus resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. It expects to file investigational new drug applications for both drug candidates in the first half of 2025. \n</p>\n<p>\n  The strategic reprioritization will impact all departments and result in an immediate reduction in headcount of about 60%, the company said. It expects the headcount reduction to be complete by the end of the fourth quarter. \n</p>\n<p>\n  Cellectar expects the restructuring will extend its cash runway into the third quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 11, 2024 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 02:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490962688","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490962688","pubTimestamp":1733941740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its workforce.The stock was recently down 76% to 30 cents. The stock closed at $1.28 on Tuesday, and is now down 90% year to date.Due to recent communications with the Food and Drug Administration regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company said Tuesday that will pursue strategic options for the further development and commercialization of this drug candidate.\"While iopofosine I 131's positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources,\" the company said.Cellectar said it will focus resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLRB":"Cellectar Biosciences Inc."},"translate_title":"Cellectar Biosciences因寻求癌症候选药物的战略选择而陷入困境，裁员60%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLRB":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its workforce. \n\n\n  The stock was recently down 76% to 30 cents. The stock closed at $1.28 on Tuesday, and is now down 90% year to date. \n\n\n  Due to recent communications with the Food and Drug Administration regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company said Tuesday that will pursue strategic options for the further development and commercialization of this drug candidate. \n\n\n  \"While iopofosine I 131's positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources,\" the company said. \n\n\n  Cellectar said it will focus resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. It expects to file investigational new drug applications for both drug candidates in the first half of 2025. \n\n\n  The strategic reprioritization will impact all departments and result in an immediate reduction in headcount of about 60%, the company said. It expects the headcount reduction to be complete by the end of the fourth quarter. \n\n\n  Cellectar expects the restructuring will extend its cash runway into the third quarter of 2025. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 13:29 ET (18:29 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490962688"}